Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT00608972. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast Cancer
Study identification
- NCT ID
- NCT00608972
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Enrollment
- 31 participants
Conditions and interventions
Conditions
Interventions
- Bevacizumab Drug
- Carboplatin Drug
- Doxil Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 15, 2008
- Primary completion
- Jul 11, 2015
- Completion
- Sep 24, 2015
- Last update posted
- Feb 7, 2023
2008 – 2015
United States locations
- U.S. sites
- 7
- U.S. states
- 1
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cooper Hospital/University Medical Center | Camden | New Jersey | 08103 | — |
| Cancer Institute of New Jersey at Hamilton | Hamilton | New Jersey | 08690 | — |
| Morristown Medical Center | Morristown | New Jersey | 07960 | — |
| Jersey Shore University Medical Center | Neptune City | New Jersey | 07753 | — |
| Saint Peter's University Hospital | New Brunswick | New Jersey | 08901 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | — |
| Overlook Medical Center | Summit | New Jersey | 07901 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00608972, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 7, 2023 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00608972 live on ClinicalTrials.gov.